Ryan Johnson

212-430-2746
ryan.johnson@fenwick.com
Partner
Litigation

Ryan
Johnson

Ryan
Johnson

Ryan
Johnson

Partner
Litigation
Industries

Ryan is a nationally recognized patent litigator who represents clients in the pharmaceutical, biotech, consumer products, telecommunications and high-tech sectors in District Courts, the Federal Circuit Court of Appeals and the Patent Trial and Appeal Board (PTAB). He also routinely advises innovative companies on the patent-related aspects of acquisitions, licenses and other transactions.

Ryan has extensive experience representing and counseling clients in the pharmaceutical industry, including at trial in their most important patent cases. He has litigated numerous cases arising under the Hatch-Waxman Act. His clients include leading biopharmaceutical companies like Pfizer, Novo Nordisk and UCB, as well as emerging companies striving to protect their IP and find a path to market. Through his many years of experience with the industry, Ryan understands the numerous regulatory, commercial and scientific challenges that these companies face, and this knowledge informs all facets of his representations. Beyond patent litigation, Ryan also has substantial experience representing pharmaceutical companies in antitrust matters and other complex commercial litigation.

Before attending law school, Ryan researched experimental recombinant DNA vaccines for the HIV virus. He also spent several years working for a leading consumer products company as a product formulator and process development engineer.

Prior to joining Fenwick, Ryan was a partner in the litigation group at a leading international law firm.

Read more

  • Representing Novo Nordisk in pending Hatch-Waxman patent infringement lawsuits brought against six generic pharmaceutical manufacturers concerning Novo Nordisk’s blockbuster type 2 diabetes therapy and best-selling product Ozempic®.
  • Representation of Novo Nordisk in a series of Hatch-Waxman patent litigations dating back to 2017 relating to its blockbuster diabetes drug Victoza®, including ongoing cases against three ANDA filers. Prevailed in claim construction proceedings against all opponents in previous litigations, which helped lead to confidential settlements in each matter.
  • Representation of Swiss biopharmaceutical company IBSA in Hatch-Waxman litigations concerning its products Flector® and Tirosint®, including ongoing litigation related to its hypothyroidism treatment product Tirosint®-SOL.
  • Representing Novo Nordisk in pending patent infringement lawsuits brought against four ANDA filers concerning Novo Nordisk’s weight-loss treatment Saxenda®.
  • Obtained highly favorable settlement for Pharmacosmos A/S and Pharmacosmos Therapeutics in patent litigation brought by a competitor in relation to Pharmacosmos’ newly launched iron deficiency anemia treatment Monoferric®.
  • Represented Pfizer and UCB in a series of District Court and PTAB trials concerning the drug Toviaz®. In the first trial against five defendants, the District Court ruled in Pfizer and UCB’s favor on all issues. In the second trial, the District Court ruled in Pfizer and UCB’s favor on all issues immediately upon the close of evidence. The PTAB upheld all challenged claims in UCB’s patents and the Federal Circuit affirmed.
  • Represented Pfizer as petitioner in an inter partes review concerning methods of treating lymphoma using monoclonal antibodies and chemotherapy. The PTAB cancelled all challenged claims as unpatentable over the prior art.
  • Represented Novo Nordisk as patent owner in an inter partes review filed by a competitor concerning methods of nanofiltering recombinant therapeutic proteins. The PTAB upheld all challenged claims in Novo Nordisk's patent.
  • Represented Pfizer at trial in a patent infringement case against eight generic manufacturers concerning the blockbuster pain and epilepsy drug Lyrica®. The U.S. District Court for the District of Delaware ruled in Pfizer's favor on all issues and the Federal Circuit affirmed.
  • Represented a pop-up COVID testing company as defendant in contesting an emergency motion for a temporary restraining order (“TRO”) halting its business based on breach of contract and IP misuse claims. The court denied the TRO.
  • Represented Pfizer in a class action lawsuit concerning the drug Celebrex® arising under federal and state antitrust and unfair competition laws.
  • Represented a large pharmaceutical company in a class action antitrust lawsuit concerning the drug Namenda®.
  • Represented foreign wireless telecommunications carriers as defendants in a patent infringement action involving over 130 parties. The U.S. District Court for the District of Maryland granted our motion to dismiss the foreign carriers for lack of personal jurisdiction, and the Federal Circuit affirmed.
  • Represented a large consumer products company in various patent infringement matters, including cases concerning internet encryption technology and social media marketing.

  • Representing Novo Nordisk in pending Hatch-Waxman patent infringement lawsuits brought against six generic pharmaceutical manufacturers concerning Novo Nordisk’s blockbuster type 2 diabetes therapy and best-selling product Ozempic®.
  • Representation of Novo Nordisk in a series of Hatch-Waxman patent litigations dating back to 2017 relating to its blockbuster diabetes drug Victoza®, including ongoing cases against three ANDA filers. Prevailed in claim construction proceedings against all opponents in previous litigations, which helped lead to confidential settlements in each matter.
  • Representation of Swiss biopharmaceutical company IBSA in Hatch-Waxman litigations concerning its products Flector® and Tirosint®, including ongoing litigation related to its hypothyroidism treatment product Tirosint®-SOL.
  • Representing Novo Nordisk in pending patent infringement lawsuits brought against four ANDA filers concerning Novo Nordisk’s weight-loss treatment Saxenda®.
  • Obtained highly favorable settlement for Pharmacosmos A/S and Pharmacosmos Therapeutics in patent litigation brought by a competitor in relation to Pharmacosmos’ newly launched iron deficiency anemia treatment Monoferric®.
  • Represented Pfizer and UCB in a series of District Court and PTAB trials concerning the drug Toviaz®. In the first trial against five defendants, the District Court ruled in Pfizer and UCB’s favor on all issues. In the second trial, the District Court ruled in Pfizer and UCB’s favor on all issues immediately upon the close of evidence. The PTAB upheld all challenged claims in UCB’s patents and the Federal Circuit affirmed.
  • Represented Pfizer as petitioner in an inter partes review concerning methods of treating lymphoma using monoclonal antibodies and chemotherapy. The PTAB cancelled all challenged claims as unpatentable over the prior art.
  • Represented Novo Nordisk as patent owner in an inter partes review filed by a competitor concerning methods of nanofiltering recombinant therapeutic proteins. The PTAB upheld all challenged claims in Novo Nordisk's patent.
  • Represented Pfizer at trial in a patent infringement case against eight generic manufacturers concerning the blockbuster pain and epilepsy drug Lyrica®. The U.S. District Court for the District of Delaware ruled in Pfizer's favor on all issues and the Federal Circuit affirmed.
  • Represented a pop-up COVID testing company as defendant in contesting an emergency motion for a temporary restraining order (“TRO”) halting its business based on breach of contract and IP misuse claims. The court denied the TRO.
  • Represented Pfizer in a class action lawsuit concerning the drug Celebrex® arising under federal and state antitrust and unfair competition laws.
  • Represented a large pharmaceutical company in a class action antitrust lawsuit concerning the drug Namenda®.
  • Represented foreign wireless telecommunications carriers as defendants in a patent infringement action involving over 130 parties. The U.S. District Court for the District of Maryland granted our motion to dismiss the foreign carriers for lack of personal jurisdiction, and the Federal Circuit affirmed.
  • Represented a large consumer products company in various patent infringement matters, including cases concerning internet encryption technology and social media marketing.

Recognition Recognition Recognition

Recognition Recognition Recognition

Recognition
IAM Patent 1000

2022 - 2023

Recognized for patent litigation in New York

Patexia

2022 - 2023

Recognized Ryan among the Top ANDA Attorneys

The Legal 500

2019 - 2020, 2023

Recognized Ryan for Patents: Litigation (full coverage)

Super Lawyers

2014 - 2019

Recognized Ryan as an Intellectual Property Litigation Rising Star in New York

Recognition
IAM Patent 1000

2022 - 2023

Recognized for patent litigation in New York

Patexia

2022 - 2023

Recognized Ryan among the Top ANDA Attorneys

The Legal 500

2019 - 2020, 2023

Recognized Ryan for Patents: Litigation (full coverage)

Super Lawyers

2014 - 2019

Recognized Ryan as an Intellectual Property Litigation Rising Star in New York